Clik here to view.
What Is in the Pipeline at GlaxoSmithKline?
743921(In license or alliance with a third party), a kinesin spindle protein (KSP) inhibitor, is an indicated therapy for cancer in phase I trials.Elacridar, an oral bioenhancer, is an indicated...
View ArticleClik here to view.
Phase II Clinical Trial of Cytogens QUADRAMET with PSA-TRICOM Initiated for...
   At the beginning of March with the sponsorship of the National Cancer Institute (NCI), Cytogen Corporation it has initiated a randomized Phase II study to evaluate QUADRAMET (samarium Sm-153...
View ArticleClik here to view.
2007 Update of What is in the Oncology Pipeline at Glaxosmithkline
   This is an update to the previous drug pipeline article covering 2006. Quite a few of the drugs from 2006 have been stopped with three new ones added. 559448, in license or other alliance...
View ArticleClik here to view.
Myriad Genetics Starts Azixa Phase II Clinical Trial for Brain Cancer Patients
   Azixa (MPC-6827) has entered Phase II clinical trials in patients with primary brain cancer. Patients with glioblastoma multiforme (GBM) will be treated with Azixa, Azixa and...
View ArticleClik here to view.
EntreMed Starts Phase II Clinical Trial of Panzem with Sutent for Kidney...
   EntreMed, Inc has commenced a Phase 2 trial to evaluate the safety and efficacy of Panzem (2-methoxyestradiol; 2ME2) alone or in combination with Sutenttermterm (sunitinibterm) in patients with...
View ArticleClik here to view.
PF-3512676 (CPG 7909) Non-Small-Cell-Lung Immuno-modulatory Treatment...
   Coley Phamaceutical Group has developed oligonucleotides which contain CpG motifs (the nucleotides cytosine and guanine in repetition) that help immune responses. The oligonucleotides illicit...
View Article
